According to Mundipharma, Napp Pharmaceuticals has launched the company’s Flutiform fluticasone propionate/formoterol fumarate k-haler breath-activated MDI in the UK. The launch is the first in Europe since Flutiform k-haler was approved for the treatment of asthma in patients aged 12 and older through the decentralized procedure in October 2017.
Mundipharma International Ltd President and CEO Alberto Martinez commented, “This launch is great news for patients with asthma in Europe, who will have the potential to benefit from this new inhaler. Patients can struggle to use their inhalers correctly and make critical errors which is associated with poor asthma control and increased exacerbations. This simple breath-triggered inhaler has been designed with patients in mind, requiring only a gentle inhalation to trigger the dose release, with the aim to help patients reduce critical errors and improve long-term outcomes.”
The original Flutiform MDI, which was developed by Skyepharma, was approved for the treatment of asthma in Europe in 2012. Skyepharma was acquired by Vectura in 2016.
Vectura Executive VP, Pharmaceutical and Device Development, Geraldine Venthoye said, “”Uncontrolled asthma is commonly associated with incorrect inhaler technique, coupled with poor adherence to therapy. The launch of this enhanced device, designed to help patients take their medicine and reduce critical errors, is a natural extension of the Flutiform franchise. Europe remains a competitive and challenging ICS-LABA market and the launch of the Flutiform k-haler will help support continued growth.”
Read the Mundipharma press release.
Read the Vectura press release.
